Olema Pharmaceuticals (NASDAQ:OLMA – Free Report) had its price objective lifted by HC Wainwright from $17.00 to $22.00 in a research report report published on Wednesday, Benzinga reports. HC Wainwright currently has a buy rating on the stock. HC Wainwright also issued estimates for Olema Pharmaceuticals’ Q3 2023 earnings at ($0.54) EPS, Q4 2023 earnings […]
Olema Pharmaceuticals (NASDAQ:OLMA – Get Free Report) and Larimar Therapeutics (NASDAQ:LRMR – Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, analyst recommendations, earnings, valuation and profitability. Insider and Institutional Ownership 81.9% of Olema […]
Equities research analysts at Oppenheimer started coverage on shares of Olema Pharmaceuticals (NASDAQ:OLMA – Get Free Report) in a research note issued to investors on Thursday, FlyOnTheWall reports. The brokerage set an “outperform” rating on the stock. Several other equities research analysts have also commented on OLMA. Lifesci Capital reiterated an “outperform” rating on shares […]
Olema Pharmaceuticals (NASDAQ:OLMA – Get Rating) had its target price reduced by equities researchers at HC Wainwright from $15.00 to $14.00 in a report issued on Wednesday, The Fly reports. HC Wainwright’s target price indicates a potential upside of 105.88% from the company’s current price. Other equities research analysts have also issued reports about the […]